Previous 10 | Next 10 |
2023-04-10 08:26:10 ET Summary GSK's dividend yield is 3.58%, slightly higher than Bristol-Myers Squibb's 3.22%. Bristol-Myers Squibb's total debt was about $40.8 billion at the end of 2022, down $4.78 billion from the previous year, thanks to the successful integration of Celgene...
2023-04-03 16:20:06 ET Legend Biotech ( NASDAQ: LEGN ) announced on Monday the appointments of Michel Vounatsos, former CEO of Biogen Inc., and John Maraganore, former CEO of Alnylam Pharma, as advisors for strategic initiatives to advance the company’s cell therapy pl...
Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the formation of a strategic advisory board a...
2023-03-31 03:22:48 ET France's consumer price inflation rate eased to 5.6% year-on-year in March 2023, down from a 38-year high of 6.3% hit in February and broadly in line with market expectations of 5.5%, a preliminary estimate showed. Still, the rate remained well above the ECB's t...
2023-03-31 01:16:07 ET Legend Biotech press release ( NASDAQ: LEGN ): FY GAAP EPS of -$0.10 beats by $1.63 . Revenue of $625.7M (+27.7% Y/Y) beats by $417.39M . For further details see: Legend Biotech GAAP EPS of -$0.10 beats by $1.63, revenue of $625.7M ...
CARTITUDE-4, a Phase 3 study of CARVYKTI ® (ciltacabtagene autoleucel) meets primary endpoint at the study’s first pre-specified interim analysis FDA clearance of IND application for LB2102 in Extensive Stage Small Cell Lung Cancer (SCLC) CARVYKTI ® ...
Nasdaq's Listing Qualifications Department notified Legend Biotech ( NASDAQ: LEGN ) that it has regained compliance with the listing rules. The company was given a notice of non-compliance in January 2023 for not filing an interim balance sheet and income statement for the quarter...
Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced that it received notice from the Listing Qualificat...
Summary Bristol-Myers Squibb's revenue was $11,406 million in Q4 2022, showing mixed results compared to previous quarters, and there are many explanations for this, which will be discussed in the article. In 2023, the company's investors should receive a dividend of $2.28 per share, up...
Summary After years of losses, Legend Biotech’s new cancer drug Cavykti offers it a chance to finally start contributing revenue to its parent, Genscript Biotech. Some analysts believe Genscript may have become profitable last year, but also worry over its mounting R&D and sa...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...